Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Nuwellis Inc (NUWE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: NUWE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $11
1 Year Target Price $11
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -71.84% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.37M USD | Price to earnings Ratio - | 1Y Target Price 11 |
Price to earnings Ratio - | 1Y Target Price 11 | ||
Volume (30-day avg) 1 | Beta 0.46 | 52 Weeks Range 0.19 - 5.84 | Updated Date 07/4/2025 |
52 Weeks Range 0.19 - 5.84 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 630.42 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -112.09% | Operating Margin (TTM) -160.71% |
Management Effectiveness
Return on Assets (TTM) -83.67% | Return on Equity (TTM) -440.77% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 55277183 | Price to Sales(TTM) 0.16 |
Enterprise Value 55277183 | Price to Sales(TTM) 0.16 | ||
Enterprise Value to Revenue 6.29 | Enterprise Value to EBITDA -0.34 | Shares Outstanding 6954640 | Shares Floating 3367168 |
Shares Outstanding 6954640 | Shares Floating 3367168 | ||
Percent Insiders 23.2 | Percent Institutions 7.89 |
Upturn AI SWOT
Nuwellis Inc
Company Overview
History and Background
Nuwellis Inc., formerly CHF Solutions, Inc., focuses on developing, manufacturing, and commercializing medical devices for ultrafiltration therapy. Founded to address fluid overload in patients with heart failure and related conditions, the company aims to provide precise and controlled fluid removal.
Core Business Areas
- Aquadex FlexFlow System: This is their primary product, designed for controlled fluid removal (ultrafiltration) in patients suffering from fluid overload, a common complication of heart failure, kidney disease, and other conditions.
Leadership and Structure
Nuwellis's leadership team consists of executives with experience in medical device development, sales, and marketing. The organizational structure includes departments for research and development, manufacturing, commercial operations, and administration.
Top Products and Market Share
Key Offerings
- Aquadex FlexFlow System: The Aquadex FlexFlow system is a standalone device and related single-use disposables for ultrafiltration. It is used in both adult and pediatric patients. Market share data is not readily available. Competitors include companies offering diuretics and other fluid management therapies. There is no single device competitor. Rather, Nuwellis is competing to change how fluids are removed, from medication to a mechanical approach.
Market Dynamics
Industry Overview
The medical device industry is dynamic, with ongoing technological advancements and increasing demand for innovative solutions in fluid management and critical care. The market is driven by the rising prevalence of heart failure, kidney disease, and related conditions that cause fluid overload.
Positioning
Nuwellis is positioned as a provider of specialized ultrafiltration therapy for patients with fluid overload. Its competitive advantage lies in its Aquadex system, which offers precise and controlled fluid removal compared to traditional diuretics.
Total Addressable Market (TAM)
The TAM for fluid overload management is substantial, encompassing a significant portion of heart failure and kidney disease patients. Nuwellis is positioned to capture a portion of this market with its Aquadex system, focusing on patients who do not respond adequately to diuretics.
Upturn SWOT Analysis
Strengths
- Specialized ultrafiltration technology
- Targeted solution for fluid overload
- Potential for improved patient outcomes compared to diuretics
- FDA cleared
Weaknesses
- Limited product portfolio
- Relatively small market presence compared to larger medical device companies
- Reliance on adoption of ultrafiltration therapy by physicians
- Ongoing need for clinical data to support efficacy
Opportunities
- Expansion into new indications beyond heart failure
- Partnerships with hospitals and healthcare systems
- International market expansion
- Development of next-generation ultrafiltration devices
- Increased awareness of ultrafiltration benefits
Threats
- Competition from established pharmaceutical companies offering diuretics
- Slow adoption of new technologies by healthcare providers
- Regulatory hurdles and reimbursement challenges
- Potential for adverse events associated with ultrafiltration
Competitors and Market Share
Key Competitors
- No direct competitor, current competitive landscape revolves around diuretics provided by big pharma.
Competitive Landscape
Nuwellisu2019s competitive advantage lies in its Aquadex system, which offers precise and controlled fluid removal compared to traditional diuretics. However, it faces the challenge of convincing physicians to adopt a new approach to fluid management.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends can only be obtained from Nuwellis Inc.'s investor relations page.
Future Projections: Future growth projections are reliant upon analyst estimates which are subject to change.
Recent Initiatives: Recent strategic initiatives may include product development, clinical trials, and commercial partnerships. Please refer to Nuwellis Inc.'s press releases and investor relations materials for more details.
Summary
Nuwellis Inc. specializes in ultrafiltration therapy, primarily with its Aquadex system. Its competitive edge is precise fluid removal compared to diuretics, but adoption by healthcare providers poses a challenge. The company operates in a growing market driven by heart failure and kidney disease prevalence. However, small company size relative to big pharma in current diuretic market and reliance on a single product line present risks, balanced by opportunities for expansion and partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Nuwellis Inc. investor relations page
- Industry reports
- Analyst estimates
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance can change rapidly. Please consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nuwellis Inc
Exchange NASDAQ | Headquaters Eden Prairie, MN, United States | ||
IPO Launch date 2012-02-16 | Interim President, Interim CEO & Chairman of the Board Mr. John L. Erb | ||
Sector Healthcare | Industry Medical Devices | Full time employees 38 | Website https://www.nuwellis.com |
Full time employees 38 | Website https://www.nuwellis.com | ||
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through specialty healthcare distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Indonesia, Israel, Italy, Panama, Romania, Singapore, Slovak Republic, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.